TransCode Therapeutics, Inc. (RNAZ), an RNA oncology company, on Thursday has completed the initial dosing of Cohort 3 in its Phase 1 clinical trial for TTX-MC138, its lead candidate designed to treat metastatic cancers.
The cohort enrolled three patients, all of whom have been dosed with TTX-MC138, with the dose administered in Cohort 3 approximately double that of Cohort 2.
The trial's Safety Review Committee has approved the opening of Cohort 3 based on safety and pharmacokinetic data from Cohorts 1 and 2, with the committee continuing to monitor the trial as new data emerges.
The trial has not reported any significant safety concerns or dose-limiting toxicities among the nine patients enrolled across the first two cohorts.
Preliminary pharmacokinetic data from Cohorts 1 and 2 suggests that TTX-MC138 demonstrates a favorable profile, consistent with previous preclinical and Phase 0 clinical trial results.
Notably, Cohort 1 demonstrated a 66 percent inhibition of miR-10b at 24 hours post-infusion, which is similar to previous findings, and Cohort 2 showed increased activity with the higher dose, further supporting the drug's pharmacokinetic and pharmacodynamic profiles.
TTX-MC138 is designed to inhibit microRNA-10b or miR-10b, which plays a critical role in the progression of many metastatic cancers.
The Phase 1 trial is assessing the safety and tolerability of TTX-MC138 in patients with metastatic solid cancers, with the potential to evaluate early clinical activity in the dose-expansion phase.
TransCode is continuing to explore the potential of TTX-MC138 to treat metastatic tumors and other cancers that overexpress miR-10b. The company is committed to advancing its RNA-based therapeutic platform to overcome challenges in RNA delivery for cancer treatment.
Currently, RNAZ is trading at $10.76 up by 22.04%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.